Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa
- PMID: 26553674
- PMCID: PMC4639482
- DOI: 10.1093/cid/civ493
Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa
Abstract
Background: A new group A meningococcal conjugate vaccine was developed to eliminate deadly meningitis epidemics in sub-Saharan Africa.
Methods: From the outset of the project, advocacy and communication strategies were developed and adjusted as the project evolved in Europe, Africa, India, and the United States. Communications efforts were evidence-based, and involved partnerships with the media and various stakeholders including African ministries of health, the World Health Organization, UNICEF, Gavi, the Centers for Disease Control and Prevention, and Médecins Sans Frontières.
Results: The implementation of an integrated communication strategy ensured the active cooperation of stakeholders while providing an organized and defined format for the dissemination of project-related developmental activities and the successful introduction of the vaccine.
Conclusions: Early in the project, a communications strategy that engaged stakeholders and potential supporters was developed. The strategy was implemented and adapted as the project matured. Linked communication proved to be key to the successful wide-scale introduction of the PsA-TT (MenAfriVac) vaccine in Africa.
Keywords: advocacy and communication; crisis communication; meningitis belt; messaging; vaccine introduction.
© 2015 World Health Organization; licensee Oxford Journals.
Similar articles
-
Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S434-41. doi: 10.1093/cid/civ551. Clin Infect Dis. 2015. PMID: 26553672 Free PMC article. Review.
-
From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project.Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S391-5. doi: 10.1093/cid/civ593. Clin Infect Dis. 2015. PMID: 26553665 Free PMC article. Review.
-
Documenting the Results of a Successful Partnership: A New Meningococcal Vaccine for Africa.Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S389-90. doi: 10.1093/cid/civ592. Clin Infect Dis. 2015. PMID: 26553664 Free PMC article. No abstract available.
-
Technical Development of a New Meningococcal Conjugate Vaccine.Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S404-9. doi: 10.1093/cid/civ595. Clin Infect Dis. 2015. PMID: 26553667 Free PMC article. Review.
-
Lessons from the Meningitis Vaccine Project.Viral Immunol. 2018 Mar;31(2):109-113. doi: 10.1089/vim.2017.0120. Epub 2017 Nov 8. Viral Immunol. 2018. PMID: 29116892 Review.
Cited by
-
Evaluation of the Impact of Meningococcal Serogroup A Conjugate Vaccine Introduction on Second-Year-of-Life Vaccination Coverage in Burkina Faso.J Infect Dis. 2019 Oct 31;220(220 Suppl 4):S233-S243. doi: 10.1093/infdis/jiz304. J Infect Dis. 2019. PMID: 31671442 Free PMC article.
-
Mobilize to vaccinate: lessons learned from social mobilization for immunization in low and middle-income countries.Hum Vaccin Immunother. 2020 May 3;16(5):1208-1214. doi: 10.1080/21645515.2019.1661206. Epub 2019 Oct 29. Hum Vaccin Immunother. 2020. PMID: 31464551 Free PMC article.
-
Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018.Vaccine. 2021 Oct 15;39(43):6370-6377. doi: 10.1016/j.vaccine.2021.09.038. Epub 2021 Sep 25. Vaccine. 2021. PMID: 34579975 Free PMC article.
-
Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S434-41. doi: 10.1093/cid/civ551. Clin Infect Dis. 2015. PMID: 26553672 Free PMC article. Review.
-
Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps.Hum Vaccin Immunother. 2018 May 4;14(5):1098-1102. doi: 10.1080/21645515.2017.1378841. Epub 2017 Nov 8. Hum Vaccin Immunother. 2018. PMID: 28968148 Free PMC article.
References
-
- Kshirsagar N, Mur N, Thatte U, Gogtay N et al. . Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007; 25(suppl 1):A101–7. - PubMed
-
- Meningitis Vaccine Project. Project advisory group (PAG). Available at: http://meningvax.org/advisory.php#pag. Accessed 15 March 2015.
-
- World Health Organization African countries to introduce new meningitis vaccine [press release]. Geneva, Switzerland: WHO, 2008. Available at: http://www.who.int/mediacentre/news/releases/2008/pr31/en/ Accessed 12 June 2014.
-
- World Health Organization Yaoundé declaration on elimination of meningococcal meningitis type A epidemics as a public health problem in Africa, 2008. Available at: http://www.who.int/immunization/newsroom/yaounde_declaration.pdf Accessed 17 April 2014.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous